4HUSSEIN M. Pegylated liposomal doxorubicin, vineristine and reduced- dose dexamet- hasone as first- line therapy for multiple myeloma[J]. Clin Lymphoma, 2003, 4(1): 18-22.
5MULLER RH, MADER K, GOHLA S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art[J]. Eur J Pharm Biopharm, 2000, 50(1): 161-177.
6MEHNERT W, MADER K. Solid lipid nanoparticles: produc- tion, characterization and applications[J]. Adv Drug Deliv Rev, 2001, 47(2-3) : 165-196.
7JACSON DV JR, SETHI VS, SPURR CL, et o.1. Intravenous vincristine infusion: phase I trial[J]. Cancer, 1981,48(12) : 2559- 2564.
8LU W, HE LC, WANG CH, et ol. The use of solid lipidnanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice[J]. Int J Biol Macromol, 2008, 43(3) : 320-324.
9JEON SI, ANDRADE JD. Protein- surface interactions in the presence of polyethylene oxide[J]. J Colloid Interface Sci, 1991, 142(1): 159-166.
10SAVIC R, LUO L, EISENBERG A, et d. Micellar nanocon- tainers distribute to defined cytoplasmic organelles[J]. Science, 2003, 300(5619) : 615-618.
